News

"These data are important for people suffering from moderate-to-severe plaque psoriasis, as up to 41 percent of those treated with ixekizumab were able to achieve clear skin at

Scheduled to reviewed by EMA under the centralized marketing authorization procedure, the application, if approved, would eanble the company to market isavuconazole in all 28 European Union member

Located in Wisconsin-Madison University Research Park, the 37,000ft2 sterile injectable fill finish facility will be a newly formed subsidiary of PSC Biotech, and will be named BioTechnique. The

All CCH three doses, including a low, medium and high dose, demonstrated an improvement in the appearance of cellulite as measured by the trial endpoints of physician and

Currently awaiting transparency on tax incentives, the GSK Consumer team has already picked out one location each in Nellore and Chittoor for the new facility, which will produce

The latest approval will pave for Cbris Lifesciences to improve capacities to develop in the regulated markets, mainly the European Union. By the end of June, Cbris had

As part of the move, hydrocodone combination products (HCP) have now been moved to the more-restrictive Schedule II substances from Schedule III. The new rule will go live

Based on data from the global AMPLIFY and AMPLIFY-EXT studies, Eliquis was also cleared for the reduction in the risk of recurrent DVT and PE following initial therapy.

Paradigm will use its advanced molecular capabilities to characterize patient tissue samples from clinical trials to better predict which patients may be sensitive or resistant to TESARO’s TSR-011.